Exact claim · Version 1 · Reviewed
“Melanotan II gives you a tan with less sun exposure.”
A verdict on this wording and scope, not a universal grade for Melanotan II.
01 · Verdict
Supported with scope
A three-person 1996 phase 1 pilot measured increased pigmentation in two of three subjects using a defined subcutaneous dose of characterised drug. That is a real pharmacological signal and nothing more: it does not establish magnitude, durability, reproducibility at consumer doses, nasal-spray dosing, or safety.
- Evidence basis
- Human pharmacology
- Scope
- Pigmentation as a measured effect in a three-person 1996 pilot study using characterised drug; not consumer products, nasal sprays, or any claim about how much tan, for how long, or at what risk.
- Category
- Mechanism and biomarkers
02 · Primary record
Check the attached evidence
01Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide, in a pilot phase-I clinical studyPubMed · Life Sciences · Human pilot · 1996
Supports the scoped claim02SCENESSE (afamelanotide) prescribing informationDailyMed · U.S. National Library of Medicine · Drug label · 2026
Supports the scoped claim
Supports the scoped claim02SCENESSE (afamelanotide) prescribing informationDailyMed · U.S. National Library of Medicine · Drug label · 2026
Supports the scoped claim
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.